A research paper just published in Science China Life Sciences reports a gastric-adaptive hydrogen polysulfide microreactor (GAPSR), which can release a large amount of hydrogen polysulfide (H₂S_n, n≥2) and inactivate H. pylori glucose-6-phosphate dehydrogenase (G6PDH) by interfering with electron transfer from glucose-6-phosphate (G6P) to nicotinamide adenine dinucleotide phosphate (NADP⁺). This discovery provides a new scheme for the treatment of Helicobacter pylori infection.

This comprehensive review analyzes cutting-edge tools and technologies in modern pharmaceutical research, focusing on artificial intelligence, multi-omics technologies, and experimental methods. The study highlights how computational methods enhance drug discovery efficiency, while omics technologies provide systematic frameworks for investigating drug mechanisms. The integration of these advanced approaches has enabled more diverse and personalized treatment strategies, though challenges remain in drug development complexity, cost-effectiveness, and operational feasibility.

A drug-resistant type of bacteria that has adapted to health care settings evolved in the past several years to weaponize an antimicrobial genetic tool, eliminating its cousins and replacing them as the dominate strain. University of Pittsburgh School of Medicine scientists made the discovery when combing through local hospital data – and then confirmed that it was a global phenomenon.